Tirzepatide (Zepbound) is currently the only GLP-1 medication that the Food and Drug Administration (FDA) has Its possible that in the future, the Food and Drug Administration (FDA) may also approve other GLP-1 receptor agonists for treating OSA in adults with overweight or obesity
Finally, the innovative application of drug-target Mendelian randomization underscores the utility of this approach in evaluating the causal effects of pharmacological interventions on disease outcomes
S Afr J Bot 141:466473 Azlan UK, Khairul Annuar NA, Mediani A, Aizat WM, Damanhuri HA, Tong X et al (2023) An insight into the neuroprotective and anti-neuroinflammatory effects and mechanisms of Moringa oleifera
Patient-Centered Care: We prioritize open communication, realistic expectations, and compassionate support throughout your treatment journey, from initial consultation through complete recovery